BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30605212)

  • 1. Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms.
    Riedlinger G; Hadigol M; Khiabanian H; Ganesan S
    JAMA Oncol; 2019 Feb; 5(2):265-267. PubMed ID: 30605212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
    Ma W; Kantarjian H; Zhang X; Yeh CH; Zhang ZJ; Verstovsek S; Albitar M
    J Mol Diagn; 2009 Jan; 11(1):49-53. PubMed ID: 19074595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
    Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
    Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
    Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
    Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
    Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
    Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
    Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
    Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases.
    Godeneche G; Gaillard N; Roy L; Mania A; Tondeur S; Chomel JC; Lavabre T; Arquizan C; Neau JP
    Cerebrovasc Dis; 2010 Jan; 29(2):206-9. PubMed ID: 20029191
    [No Abstract]   [Full Text] [Related]  

  • 11. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.
    Goodyer M; Langabeer SE; Haslam K; Murphy K
    Pathol Oncol Res; 2016 Jan; 22(1):229-30. PubMed ID: 26450123
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical implications of JAK2 mutations in myeloproliferative disorders.
    Knoops L; Hermans C; Ferrant A; Constantinescu SN
    Acta Clin Belg; 2008; 63(2):93-8. PubMed ID: 18575049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
    Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
    Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations.
    Yang HS
    Cancer Biomark; 2016; 17(4):383-389. PubMed ID: 27662324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders.
    Xiao Z; Zhang Y; Li L; Nie L; Yang L; Xu S
    Haematologica; 2008 May; 93(5):787-8. PubMed ID: 18450736
    [No Abstract]   [Full Text] [Related]  

  • 16. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.
    Colaizzo D; Amitrano L; Tiscia GL; Iannaccone L; Gallone A; Grandone E; Guardascione MA; Margaglione M
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):459-62. PubMed ID: 18600100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac JAK2 mutation V617F in a patient with cardiomyopathy and myeloproliferative disease.
    Gattenlohner S; Ertl G; Einsele H; Kircher S; Muller-Hermelink HK; Marx A
    Ann Intern Med; 2008 Jul; 149(1):69-71. PubMed ID: 18591647
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
    Schaub FX; Looser R; Li S; Hao-Shen H; Lehmann T; Tichelli A; Skoda RC
    Blood; 2010 Mar; 115(10):2003-7. PubMed ID: 20061559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
    Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
    Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.